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fveryone is aware of the enormous progress that has been
ade with regard to cardiovascular disease over the past half
entury. Percutaneous intervention, defibrillators, heart
ransplant, and a variety of pharmaceutical agents have
educed the morbidity and prolonged the life of patients
ith coronary disease and/or heart failure. No one could
eny that the field of cardiovascular medicine has been a
otbed of innovation and advancement.
The credit for the progress in cardiovascular medicine
ust be attributed to a number of groups. Researchers are,
f course, the first group that comes to mind. The process of
iscovery is fundamental to the progress of any field of
edicine. Vision and inquisitiveness, coupled with hard
ork, perseverance, and often a little luck, are required to
evelop important new knowledge. Since, by definition,
esearch deals with the unknown, investigators must be
repared not only for the possibility that their experiment
ill fail, but also that it may render a negative answer that
oes not lead to an important clinical advance. For every
tudy that provides a major breakthrough, there are many,
any others that render small increments of knowledge or
rovide the groundwork for others to move forward. Enor-
ous credit must be given to those in the research commu-
ity who endure intellectual uncertainty and professional
nsecurity to define new mechanisms and therapies for
ardiovascular disease.
Investigators, of course, cannot perform their work
ithout considerable assistance. Whether it is molecular
iology or a randomized multicenter clinical trial, quality
esearch requires financial and administrative resources.
e have been fortunate to have a supportive infrastruc-
ure throughout the industrialized world which has nur-
ured investigators and facilitated our efforts. Society has
sually been generous in providing financial support for
edical investigation. Private industry, while a possible
eneficiary of the results, must also be acknowledged for
he investment they have made in research. We are very
ikely living in a time of unprecedented support for the
esearch enterprise.
However, there is one group without whom important
edical advances could not occur, and who I believe are
ften overlooked when assigning credit. I am referring to
he patients who participate in medical research. I must
dmit, I became anxious and diaphoretic when reading
he side effects on the package insert of approved medi-
ations that I take. Research participants voluntarily txpose themselves to an uncertain degree of discomfort
nd risk, often with little or no expectation of benefit for
hemselves. These individuals generally make more of a
ommitment to the research project in terms of their own
iscomfort and potential adverse events than do even the
nvestigators.
My appreciation of research subjects has been reinforced
y a recent study we have undertaken involving the admin-
stration of stem cells to postinfarct patients. As with any
hase one safety and dosing trial, the unknowns are con-
iderable. This uncertainty is amplified somewhat by the
ature of the agent being evaluated—that is autologous
esenchymal stem cells. Patients participating in the pro-
ocol must undergo extensive screening for undetected
ubclinical disease and be hospitalized for 72 h. This is for
he possibility of a benefit which must be weighed against
eceiving a placebo, or ineffective therapy, or a possible
dverse event. Nevertheless, nearly every patient we have
pproached thus far has shown a genuine interest in being
ble to participate. Certainly, it would be hard to argue that
hey do not understand the risks which are explained to
hem in great detail.
In the foregoing study, the patients have at least some
hance of benefit. I have conducted imaging studies in the
ast where the patients would receive no clinical benefit
hemselves. In fact, the data are often blinded until after a
herapeutic decision is made. Nevertheless, these patients
ypically agree to participate in the study in the unselfish
ope that it will “help someone else.” There is no question
hat both we as investigators and society as a whole owes
hese individuals a large debt of gratitude.
Werner Forssman set a good example for us when he
emonstrated the feasibility of catheterization by passing
catheter to his own right heart. Perhaps we as physi-
ians should follow the example by being more proactive
n participating in research protocols. The necessity of a
athophysiological state likely excludes us from many
rotocols. However, there are many procedures inside
nd outside of cardiology for which we would qualify.
his would provide a clear statement that our own
ommitment to increasing knowledge is equal to that of
ur patients.
The worldwide research effort in cardiovascular disease
as begotten fantastic benefits for society. While the pro-
ession basks in the glow of achievement, we must not forget
he contributions of the research participants who made the
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ndividuals who voluntarily enroll in investigational proto-
ols should serve as both an example and inspiration for the
est of us. In my opinion, they are the unsung heroes of our
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n-Chief, Journal of the American College of Cardiology, 3655 Nobel
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